Xenetic Biosciences Stock Performance
| XBIO Stock | USD 4.01 0.02 0.50% |
Xenetic Biosciences has a performance score of 1 on a scale of 0 to 100. The firm maintains a market beta of 0.2, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Xenetic Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xenetic Biosciences is expected to be smaller as well. Xenetic Biosciences right now maintains a risk of 5.09%. Please check out Xenetic Biosciences value at risk, as well as the relationship between the skewness and day median price , to decide if Xenetic Biosciences will be following its historical returns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Xenetic Biosciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy forward indicators, Xenetic Biosciences is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (2.56) | Five Day Return 3.81 | Year To Date Return 6.72 | Ten Year Return 27 | All Time Return (58.77) |
Last Split Factor 1:10 | Dividend Date 2019-06-25 | Last Split Date 2023-05-15 |
1 | Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference | 09/11/2024 |
2 | Xenetic Biosciences Inc Short Interest Down 50.0 percent in September | 10/11/2024 |
3 | Xenetic Biosciences files for 50M mixed securities shelf | 10/21/2024 |
4 | Acquisition by Kornberg Roger D. of 25000 shares of Xenetic Biosciences at 1.44 subject to Rule 16b-3 | 10/29/2024 |
5 | Xenetic Biosciences Announces Departure of Two Board Members | 11/01/2024 |
6 | Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical ... | 11/12/2024 |
7 | Xenetic Biosciences Third Quarter 2024 Earnings Misses Expectations - Yahoo Finance | 11/15/2024 |
| Begin Period Cash Flow | 13.1 M |
Xenetic |
Xenetic Biosciences Relative Risk vs. Return Landscape
If you would invest 415.00 in Xenetic Biosciences on August 24, 2024 and sell it today you would lose (14.00) from holding Xenetic Biosciences or give up 3.37% of portfolio value over 90 days. Xenetic Biosciences is currently generating 0.072% in daily expected returns and assumes 5.0904% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Xenetic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xenetic Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xenetic Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xenetic Biosciences, and traders can use it to determine the average amount a Xenetic Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0141
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | XBIO | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.09 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Xenetic Biosciences is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xenetic Biosciences by adding it to a well-diversified portfolio.
Xenetic Biosciences Fundamentals Growth
Xenetic Stock prices reflect investors' perceptions of the future prospects and financial health of Xenetic Biosciences, and Xenetic Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xenetic Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | (684.62 K) | ||||
| Shares Outstanding | 1.54 M | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 2.44 X | ||||
| Revenue | 2.54 M | ||||
| Gross Profit | 1.16 M | ||||
| EBITDA | (4.52 M) | ||||
| Net Income | (4.13 M) | ||||
| Cash And Equivalents | 14.93 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 809.59 K | ||||
| Current Ratio | 12.02 X | ||||
| Book Value Per Share | 6.36 X | ||||
| Cash Flow From Operations | (4.11 M) | ||||
| Earnings Per Share | (2.72) X | ||||
| Market Capitalization | 6.15 M | ||||
| Total Asset | 10.61 M | ||||
| Retained Earnings | (193.23 M) | ||||
| Working Capital | 8.78 M | ||||
| Current Asset | 1.21 M | ||||
| Current Liabilities | 4.97 M | ||||
About Xenetic Biosciences Performance
By examining Xenetic Biosciences' fundamental ratios, stakeholders can obtain critical insights into Xenetic Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Xenetic Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.01 | 0.01 | |
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (0.42) | (0.44) |
Things to note about Xenetic Biosciences performance evaluation
Checking the ongoing alerts about Xenetic Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xenetic Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xenetic Biosciences had very high historical volatility over the last 90 days | |
| Xenetic Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.54 M. Net Loss for the year was (4.13 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Xenetic Biosciences currently holds about 14.93 M in cash with (4.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Xenetic Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: Xenetic Biosciences Third Quarter 2024 Earnings Misses Expectations - Yahoo Finance |
- Analyzing Xenetic Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xenetic Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Xenetic Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xenetic Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xenetic Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xenetic Biosciences' stock. These opinions can provide insight into Xenetic Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.72) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.